Fidelity Investments
HSCS icon

Fidelity Investments’s Heart Test Laboratories HSCS Stock Holding History

Fidelity Investments’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$17 – 5533
2023
Q4 		$17 Buy
+1
New +$25 ﹤0.01% 5244

Other funds holding HSCS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TWM
Tradition Wealth Management Edina, Minnesota $1.41B AUM 19.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
HWA
HCR Wealth Advisors Los Angeles, California $1.12B AUM 33.13% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
OLVIG
Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments's HSCS Position: Q1 2024 in Review

Fidelity Investments sold out of Heart Test Laboratories (HSCS) in Q1 2024, closing a stake of 1 share — an estimated $17 sold.

Fidelity Investments first reported a position in HSCS in Q4 2023 and held it in 1 quarter. The position peaked at $17 in Q4 2023. 22 funds tracked by Wall St. Rank hold HSCS as of Q1 2024.

  • Fidelity Investments reported no remaining Heart Test Laboratories position as of Q1 2024 after selling out during the quarter.
  • Fidelity Investments sold 1 Heart Test Laboratories share in Q1 2024, an estimated $17.
  • Fidelity Investments first reported a position in Heart Test Laboratories in Q4 2023 and held it in 1 quarter.
  • Fidelity Investments's Heart Test Laboratories position peaked at $17 in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.